These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15732250)

  • 21. Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
    Mendoza FJ; Espino PS; Cann KL; Bristow N; McCrea K; Los M
    Arch Immunol Ther Exp (Warsz); 2005; 53(1):47-60. PubMed ID: 15761376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibody therapy in hematology and oncology--2].
    Kneba M; Schrader C; Köhne H
    Med Klin (Munich); 2009 Jan; 104(1):28-49. PubMed ID: 19142594
    [No Abstract]   [Full Text] [Related]  

  • 23. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth and differentiation control.
    Francis GE; Dómine M
    Cancer Chemother Biol Response Modif; 1992; 13():230-85. PubMed ID: 1389911
    [No Abstract]   [Full Text] [Related]  

  • 25. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
    Ashkenazi A
    Nat Rev Drug Discov; 2008 Dec; 7(12):1001-12. PubMed ID: 18989337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. General morphological and biological features of neoplasms: integration of molecular findings.
    Diaz-Cano SJ
    Histopathology; 2008 Jul; 53(1):1-19. PubMed ID: 18282144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines.
    Kai K; D'Costa S; Sills RC; Kim Y
    Cancer Lett; 2009 Jun; 278(1):49-55. PubMed ID: 19178995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of death receptors--relevance in cancer therapies.
    de Thonel A; Eriksson JE
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):123-32. PubMed ID: 16126242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor cell metabolism: cancer's Achilles' heel.
    Kroemer G; Pouyssegur J
    Cancer Cell; 2008 Jun; 13(6):472-82. PubMed ID: 18538731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New targets in oncology drug development.
    Verweij J
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):754-5. PubMed ID: 16258482
    [No Abstract]   [Full Text] [Related]  

  • 31. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades.
    Bidwell GL; Raucher D
    Expert Opin Drug Deliv; 2009 Oct; 6(10):1033-47. PubMed ID: 19637980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells.
    Lee SJ; Cho YH; Park K; Kim EJ; Jung KH; Park SS; Kim WJ; Moon SK
    Biochem Pharmacol; 2008 Jun; 75(12):2289-300. PubMed ID: 18468578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation.
    Gewirtz DA; Holt SE; Elmore LW
    Biochem Pharmacol; 2008 Oct; 76(8):947-57. PubMed ID: 18657518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Akt/PKB pathway: molecular target for cancer drug discovery.
    Cheng JQ; Lindsley CW; Cheng GZ; Yang H; Nicosia SV
    Oncogene; 2005 Nov; 24(50):7482-92. PubMed ID: 16288295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
    Lorigan P; Eisen T; Hauschild A
    Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins in tumor suppression.
    Sassano A; Platanias LC
    Cancer Lett; 2008 Feb; 260(1-2):11-9. PubMed ID: 18180097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.